GeneDx Holdings Corp.

Informe acción NasdaqGS:WGS

Capitalización de mercado: US$2.2b

GeneDx Holdings Dirección

Dirección controles de criterios 3/4

El CEO de GeneDx Holdings es Katherine Stueland , nombrado en May 2022, tiene una permanencia de 2.5 años. compensación anual total es $3.58M, compuesta por 18.9% salario y 81.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.22% de las acciones de la empresa, por valor de $4.72M. La antigüedad media del equipo directivo y de la junta directiva es de 1.1 años y 3.3 años, respectivamente.

Información clave

Katherine Stueland

Chief Executive Officer (CEO)

US$3.6m

Compensación total

Porcentaje del salario del CEO18.9%
Permanencia del CEO2.5yrs
Participación del CEO0.2%
Permanencia media de la dirección1.1yrs
Promedio de permanencia en la Junta Directiva3.3yrs

Actualizaciones recientes de la dirección

Recent updates

GeneDx Holdings Corp.'s (NASDAQ:WGS) P/S Is Still On The Mark Following 40% Share Price Bounce

Nov 23
GeneDx Holdings Corp.'s (NASDAQ:WGS) P/S Is Still On The Mark Following 40% Share Price Bounce

US$76.67 - That's What Analysts Think GeneDx Holdings Corp. (NASDAQ:WGS) Is Worth After These Results

Nov 01
US$76.67 - That's What Analysts Think GeneDx Holdings Corp. (NASDAQ:WGS) Is Worth After These Results

GeneDx Holdings: Phenomenal Gains, More Upside Potential In Medium Term

Oct 30

GeneDx Holdings: Stock To Keep Outperforming As Business Momentum Persists

Oct 21

After Leaping 53% GeneDx Holdings Corp. (NASDAQ:WGS) Shares Are Not Flying Under The Radar

Oct 04
After Leaping 53% GeneDx Holdings Corp. (NASDAQ:WGS) Shares Are Not Flying Under The Radar

Is GeneDx Holdings (NASDAQ:WGS) Using Debt Sensibly?

Aug 29
Is GeneDx Holdings (NASDAQ:WGS) Using Debt Sensibly?

GeneDx Holdings: Profits On The Horizon For AI Driven Health Platform

Aug 19

Market Participants Recognise GeneDx Holdings Corp.'s (NASDAQ:WGS) Revenues Pushing Shares 28% Higher

Jul 27
Market Participants Recognise GeneDx Holdings Corp.'s (NASDAQ:WGS) Revenues Pushing Shares 28% Higher

GeneDx Holdings Corp.'s (NASDAQ:WGS) 30% Jump Shows Its Popularity With Investors

Jun 12
GeneDx Holdings Corp.'s (NASDAQ:WGS) 30% Jump Shows Its Popularity With Investors

GeneDx Holdings: Mapping A Path To Leadership In Pediatric Genetic Testing

Jun 06

Further Upside For GeneDx Holdings Corp. (NASDAQ:WGS) Shares Could Introduce Price Risks After 42% Bounce

Apr 24
Further Upside For GeneDx Holdings Corp. (NASDAQ:WGS) Shares Could Introduce Price Risks After 42% Bounce

GeneDx Holdings Corp. (NASDAQ:WGS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$9.13

Feb 23
GeneDx Holdings Corp. (NASDAQ:WGS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$9.13

The Market Lifts GeneDx Holdings Corp. (NASDAQ:WGS) Shares 107% But It Can Do More

Feb 22
The Market Lifts GeneDx Holdings Corp. (NASDAQ:WGS) Shares 107% But It Can Do More

Improved Revenues Required Before GeneDx Holdings Corp. (NASDAQ:WGS) Stock's 56% Jump Looks Justified

Dec 20
Improved Revenues Required Before GeneDx Holdings Corp. (NASDAQ:WGS) Stock's 56% Jump Looks Justified

Analyst Forecasts Just Became More Bearish On GeneDx Holdings Corp. (NASDAQ:WGS)

Nov 02
Analyst Forecasts Just Became More Bearish On GeneDx Holdings Corp. (NASDAQ:WGS)

Not Many Are Piling Into GeneDx Holdings Corp. (NASDAQ:WGS) Stock Yet As It Plummets 49%

Nov 01
Not Many Are Piling Into GeneDx Holdings Corp. (NASDAQ:WGS) Stock Yet As It Plummets 49%

Sema4 names Kevin Feeley as CFO

Aug 26

Things Look Grim For Sema4 Holdings Corp. (NASDAQ:SMFR) After Today's Downgrade

Aug 20
Things Look Grim For Sema4 Holdings Corp. (NASDAQ:SMFR) After Today's Downgrade

Sema4 Holdings Corp. (NASDAQ:SMFR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aug 19
Sema4 Holdings Corp. (NASDAQ:SMFR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Sema4 Q2 2022 Earnings Preview

Aug 12

Sema4 Holdings, Big Data For Precision Medicine Solutions

Jul 18

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Katherine Stueland en comparación con los beneficios de GeneDx Holdings?
FechaCompensación totalSalarioIngresos de la empresa
Sep 30 2024n/an/a

-US$83m

Jun 30 2024n/an/a

-US$117m

Mar 31 2024n/an/a

-US$135m

Dec 31 2023US$4mUS$675k

-US$176m

Sep 30 2023n/an/a

-US$459m

Jun 30 2023n/an/a

-US$494m

Mar 31 2023n/an/a

-US$533m

Dec 31 2022US$12mUS$454k

-US$549m

Compensación vs. Mercado: La compensación total de Katherine($USD3.58M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD5.54M).

Compensación vs. Ingresos: La compensación de Katherine ha sido consistente con los resultados de la empresa en el último año.


CEO

Katherine Stueland (48 yo)

2.5yrs

Permanencia

US$3,575,335

Compensación

Ms. Katherine A. Stueland serves as Chief Executive Officer & Director at GeneDx Holdings Corp. (formerly known as Sema4 Holdings Corp.) since May 2022 and serves as its President. She served as President...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Katherine Stueland
President2.5yrsUS$3.58m0.22%
$ 4.7m
Kevin Feeley
Chief Financial Officer2.3yrsUS$1.57m0.16%
$ 3.5m
Karen Ponchner
Head of Operations1.1yrssin datossin datos
Eric Olivares
Chief Product & Technology Officerless than a yearsin datossin datos
Jami Biliboaca
Head of People Strategyless than a yearsin datossin datos
Paul Kruszka
Chief Medical Officer2.5yrssin datossin datos
Melanie Duquette
Chief Growth Officer1.2yrssin datossin datos
Sabrina Dunbar
Chief of Staffno datasin datossin datos
Britt Johnson
Head of Medical Affairsless than a yearsin datossin datos

1.1yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de WGS no se considera experimentado ( 1.1 años antigüedad media), lo que sugiere un nuevo equipo.


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Katherine Stueland
President2.5yrsUS$3.58m0.22%
$ 4.7m
Joshua Ruch
Independent Director7yrsUS$162.00k0.71%
$ 15.3m
Richard Pfenniger
Director2.6yrsUS$147.00k0.10%
$ 2.2m
Keith Meister
Independent Director2.8yrsUS$162.00k0.026%
$ 567.2k
Eli Casdin
Independent Director4.3yrsUS$154.50k0.028%
$ 597.7k
Jason Ryan
Chairman of the Board3.3yrsUS$992.46k0.53%
$ 11.5m
Emily Leproust
Independent Director4.2yrsUS$160.75k0.030%
$ 657.3k

3.3yrs

Permanencia media

50.5yo

Promedio de edad

Junta con experiencia: La junta directiva de WGS se considera experimentada (3.3 años de antigüedad promedio).